CA2594449A1 - 1,3-diaryl substituted ureas as modulators of kinase activity - Google Patents
1,3-diaryl substituted ureas as modulators of kinase activity Download PDFInfo
- Publication number
- CA2594449A1 CA2594449A1 CA002594449A CA2594449A CA2594449A1 CA 2594449 A1 CA2594449 A1 CA 2594449A1 CA 002594449 A CA002594449 A CA 002594449A CA 2594449 A CA2594449 A CA 2594449A CA 2594449 A1 CA2594449 A1 CA 2594449A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- phenyl
- indol
- ylmethyl
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64388605P | 2005-01-14 | 2005-01-14 | |
| US60/643,886 | 2005-01-14 | ||
| US73299905P | 2005-11-02 | 2005-11-02 | |
| US60/732,999 | 2005-11-02 | ||
| PCT/US2006/001272 WO2006076593A1 (en) | 2005-01-14 | 2006-01-13 | 1,3-diaryl substituted ureas as modulators of kinase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2594449A1 true CA2594449A1 (en) | 2006-07-20 |
Family
ID=36250833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002594449A Abandoned CA2594449A1 (en) | 2005-01-14 | 2006-01-13 | 1,3-diaryl substituted ureas as modulators of kinase activity |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060199846A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2397478A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008526988A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101292598B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102267978A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006204790B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2594449A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2393741T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL184494A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ556433A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2402544C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI378925B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006076593A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2397478A1 (en) * | 2005-01-14 | 2011-12-21 | CGI Pharmaceuticals, Inc. | 1,3-diaryl substituted ureas as modulators of kinase activity. |
| US7777040B2 (en) * | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| JP5236499B2 (ja) * | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| CN101058561B (zh) * | 2006-04-19 | 2011-01-26 | 苏州爱斯鹏药物研发有限责任公司 | 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途 |
| JP2011520809A (ja) * | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2010036316A1 (en) * | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| AU2010289143A1 (en) * | 2009-08-24 | 2012-02-16 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
| CN103288684B (zh) * | 2013-05-03 | 2014-12-10 | 西安交通大学 | 一种具有抗肿瘤活性的联苯脲化合物及其制备方法 |
| JP6545197B2 (ja) * | 2014-05-28 | 2019-07-17 | ノバルティス アーゲー | 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用 |
| CN104725319A (zh) * | 2015-03-11 | 2015-06-24 | 西安交通大学 | 一种具有抗肿瘤活性的1h-吲唑-3-氨基联苯脲类化合物及其制备方法和应用 |
| MA56193A (fr) * | 2019-06-14 | 2022-04-20 | Ifm Due Inc | Composés et compositions pour traiter des états associés à une activité de sting |
| CN113527254B (zh) * | 2021-07-07 | 2022-05-03 | 北京华氏信华科生物科技有限公司 | 7-甲氧基-1h-吲哚类化合物、制备方法、药物组合物及应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE447653B (sv) * | 1978-11-14 | 1986-12-01 | Eisai Co Ltd | Imidazolderivat samt farmaceutisk komposition innehallande sadant derivat |
| US5395817A (en) * | 1992-01-22 | 1995-03-07 | Imperial Chemical Industries Plc | N-arylindoles and their use as herbicides |
| EP0630373A1 (en) * | 1992-03-12 | 1994-12-28 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
| DE4327027A1 (de) * | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| PL192628B1 (pl) * | 1996-04-23 | 2006-11-30 | Vertex Pharma | Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji |
| CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| JP4437270B2 (ja) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | 置換複素環式尿素を用いたrafキナーゼの阻害 |
| ATE291011T1 (de) * | 1997-12-22 | 2005-04-15 | Bayer Pharmaceuticals Corp | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
| US6858577B1 (en) * | 1999-06-29 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | Indole peptidomimetics as thrombin receptor antagonists |
| US6627647B1 (en) * | 2000-03-23 | 2003-09-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents |
| US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US20030073692A1 (en) * | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2003072541A2 (en) * | 2001-09-27 | 2003-09-04 | Smithkline Beecham Corporation | Chemical compounds |
| TWI323658B (en) * | 2001-12-06 | 2010-04-21 | Nat Health Research Institutes | Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same |
| TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
| US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| DK1478358T3 (da) * | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| US20050124620A1 (en) * | 2002-04-09 | 2005-06-09 | Martyn Frederickson | Pharmaceutical compounds |
| EP1495016A2 (en) * | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| BR0309398A (pt) * | 2002-04-19 | 2005-02-01 | Cellular Genomics Inc | Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase |
| AU2003270489A1 (en) * | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| JP4799864B2 (ja) * | 2002-09-23 | 2011-10-26 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン |
| KR20060010709A (ko) * | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진 |
| US7189723B2 (en) * | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US20040235892A1 (en) * | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) * | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| ES2465469T3 (es) * | 2005-01-14 | 2014-06-05 | Gilead Connecticut, Inc. | Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa |
| EP2397478A1 (en) * | 2005-01-14 | 2011-12-21 | CGI Pharmaceuticals, Inc. | 1,3-diaryl substituted ureas as modulators of kinase activity. |
| US7777040B2 (en) * | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
-
2006
- 2006-01-13 EP EP11181551A patent/EP2397478A1/en not_active Withdrawn
- 2006-01-13 EP EP06718359A patent/EP1858879B1/en not_active Expired - Lifetime
- 2006-01-13 NZ NZ556433A patent/NZ556433A/en not_active IP Right Cessation
- 2006-01-13 JP JP2007551409A patent/JP2008526988A/ja active Pending
- 2006-01-13 RU RU2007130895/04A patent/RU2402544C2/ru not_active IP Right Cessation
- 2006-01-13 TW TW095101448A patent/TWI378925B/zh not_active IP Right Cessation
- 2006-01-13 US US11/331,346 patent/US20060199846A1/en not_active Abandoned
- 2006-01-13 ES ES06718359T patent/ES2393741T3/es not_active Expired - Lifetime
- 2006-01-13 KR KR1020077018205A patent/KR101292598B1/ko not_active Expired - Fee Related
- 2006-01-13 CA CA002594449A patent/CA2594449A1/en not_active Abandoned
- 2006-01-13 CN CN2011101127260A patent/CN102267978A/zh active Pending
- 2006-01-13 AU AU2006204790A patent/AU2006204790B2/en not_active Ceased
- 2006-01-13 WO PCT/US2006/001272 patent/WO2006076593A1/en not_active Ceased
-
2007
- 2007-07-09 IL IL184494A patent/IL184494A/en not_active IP Right Cessation
-
2012
- 2012-09-21 JP JP2012208429A patent/JP2013028628A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013028628A (ja) | 2013-02-07 |
| RU2402544C2 (ru) | 2010-10-27 |
| KR101292598B1 (ko) | 2013-08-05 |
| TW200639165A (en) | 2006-11-16 |
| NZ556433A (en) | 2010-10-29 |
| CN102267978A (zh) | 2011-12-07 |
| EP2397478A1 (en) | 2011-12-21 |
| EP1858879A1 (en) | 2007-11-28 |
| AU2006204790A1 (en) | 2006-07-20 |
| IL184494A (en) | 2013-04-30 |
| AU2006204790B2 (en) | 2012-08-23 |
| KR20070113200A (ko) | 2007-11-28 |
| TWI378925B (en) | 2012-12-11 |
| EP1858879B1 (en) | 2012-06-06 |
| RU2007130895A (ru) | 2009-02-20 |
| JP2008526988A (ja) | 2008-07-24 |
| US20060199846A1 (en) | 2006-09-07 |
| ES2393741T3 (es) | 2012-12-27 |
| IL184494A0 (en) | 2007-10-31 |
| WO2006076593A1 (en) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1858877B1 (en) | 1,3 substituted diaryl ureas as modulators of kinase activity | |
| US8222421B2 (en) | Certain substituted ureas, as modulators of kinase activity | |
| CA3215564C (en) | Methods and compounds for restoring mutant p53 function | |
| JP4926973B2 (ja) | 治療化合物としての、イミダゾ[4,5−b]ピリジン−2−オンおよびオキサゾロ[4,5−b]ピリジン−2−オン化合物ならびにそれらの類似体 | |
| AU2009245715B2 (en) | Trisubstituted pyrazoles as acetylcholine receptor modulators | |
| HUE029370T2 (hu) | Rákellenes aktivitású vegyületek | |
| TWI426908B (zh) | 特定化學品、組成物及方法 | |
| JP5518887B2 (ja) | 四置換ピリダジンヘッジホッグ経路アンタゴニスト | |
| JP2013028628A (ja) | キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素 | |
| CN114057771B (zh) | 大环化合物及其制备方法和应用 | |
| US20090176809A1 (en) | Raf inhibitor compounds and methods | |
| PT885212E (pt) | Quinoxalinodionas | |
| TWI434840B (zh) | 吡唑啶-3-酮衍生物 | |
| WO2011046991A2 (en) | Certain substituted ureas as modulators of kinase activity | |
| US7777051B2 (en) | Asymmetric benzimidazoles and related compounds as potassium channel modulators | |
| ES2547072T3 (es) | Heteroaril benzamidas, composiciones y métodos de utilización | |
| CN101163691A (zh) | 作为激酶活性调节剂的1,3-二芳基取代的脲 | |
| HK1114392A (en) | 1,3-diaryl substituted ureas as modulators of kinase activity | |
| WO2025145182A1 (en) | Selective inhibitors of t cell activation | |
| HK1172510A (en) | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140929 |